Loading...
Loading...
posted better-than expected fourth quarter results on Monday, but offered a revenue forecast shy of analysts' consensus.
The San Diego-based drug development company changed hands recently in the extended session at $15.30, up $0.08.
For 2015, Halozyme forecast revenue of $85 million to $95 million, versus Wall Street's expectation of $97.7 million.
Halozyme also forecast a net cash burn rate of $35 million to $45 million for 2015, and posted cash and cash equivalents as of December 31 of $61.39 million.
Halozyme expects first quarter royalty revenues of between $6 million to $7 million, up from $4 million in the fourth quarter.
The company's fourth quarter net loss narrowed to $5.3 million, or $0.04 a share, from $22.0 million, or $0.19 a share, last year.
Revenue more than doubled to $30.4 million, from $12.5 million.
Wall Street expected a loss of $0.07 a share, on revenue of $25.59 million.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in